These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 36644836

  • 1. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD.
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [Abstract] [Full Text] [Related]

  • 2. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, Briceño A, Cabrera E, Cobo-Marcos M, Dominguez F, Gonzalez-Lopez E, Segovia J, Lara-Pezzi E, Garcia-Pavia P.
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [Abstract] [Full Text] [Related]

  • 3. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y, Ioannou A, Patel RK, Chacko L, Karia N, Riefolo M, Porcari A, Rauf MU, Starr N, Ganesananthan S, Blakeney I, Kaza N, Filisetti S, Bolhuis RE, Rowczenio D, Gilbertson J, Hutt D, Mahmood S, Lachmann HJ, Wechalekar AD, Kotecha T, Knight DS, Coghlan JG, Petrie A, Whelan CJ, Venneri L, Martinez-Naharro A, Hawkins P, Fontana M, Gillmore JD.
    Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
    [Abstract] [Full Text] [Related]

  • 4. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D, Helmke S, Winburn M, Kurian D, Raiszadeh F, Teruya S, Cohn E, Einstein AJ, Miller EJ, Connors LH, Maurer MS, Ruberg FL.
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [Abstract] [Full Text] [Related]

  • 5. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V, Grittner U, Beetz C, Skripuletz T, Juenemann M, Krämer HH, Hahn K, Rieth A, Schaechinger V, Patten M, Tanislav C, Achenbach S, Assmus B, Knebel F, Gingele S, Skrahin A, Hartkamp J, Förster TM, Roesner S, Pereira C, Rolfs A.
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS.
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [Abstract] [Full Text] [Related]

  • 7. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS, Gude E, Hodt A, Knudsen EC.
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.
    Kim D, Youn JC, Lee HW, Oh J, Son JW, Cho HJ, Lee S, Shah NR, Kittleson MM, Jeon ES.
    J Korean Med Sci; 2024 May 20; 39(19):e163. PubMed ID: 38769922
    [Abstract] [Full Text] [Related]

  • 9. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.
    Dungu JN, Papadopoulou SA, Wykes K, Mahmood I, Marshall J, Valencia O, Fontana M, Whelan CJ, Gillmore JD, Hawkins PN, Anderson LJ.
    Circ Heart Fail; 2016 Sep 20; 9(9):. PubMed ID: 27618855
    [Abstract] [Full Text] [Related]

  • 10. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
    Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, Knight D, Kotecha T, Martinez-Naharro A, Masi A, Porcari A, Brown J, Patel K, Manisty C, Moon J, Rowczenio D, Gilbertson JA, Sinagra G, Lachmann H, Wechalekar A, Petrie A, Whelan C, Hawkins PN, Gillmore JD, Fontana M.
    Eur J Heart Fail; 2022 Dec 20; 24(12):2355-2363. PubMed ID: 36575133
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
    Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S.
    Amyloid; 2018 Mar 20; 25(1):62-67. PubMed ID: 29424556
    [Abstract] [Full Text] [Related]

  • 12. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
    Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR.
    Am Heart J; 2012 Aug 20; 164(2):222-228.e1. PubMed ID: 22877808
    [Abstract] [Full Text] [Related]

  • 13. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
    Takashio S, Tokitsu T, Matsukawa M, Sakaino N, Fujimoto K, Sakamoto T, Noda K, Tsunoda R, Misumi I, Hirai N, Doi H, Koide S, Mizuno Y, Hirose T, Kurokawa H, Kajiwara I, Ohba K, Miyamoto S, Araki S, Yamamoto E, Matsushita K, Ueda M, Tsujita K, Kumamoto Cardiac Amyloid Survey Investigators.
    J Cardiol; 2022 Jul 20; 80(1):49-55. PubMed ID: 35078683
    [Abstract] [Full Text] [Related]

  • 14. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL, Blaner WS, Chiuzan C, Connors LH, Einstein AJ, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung WK, Cohn E, Miller EJ, Kelly JW, Maurer MS.
    J Am Heart Assoc; 2023 Apr 18; 12(8):e028534. PubMed ID: 37066788
    [Abstract] [Full Text] [Related]

  • 15. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis.
    Gallego Delgado M, Gayán Ordás J, Eiros R, García Berrocal B, Sánchez PL, Villacorta E.
    Med Clin (Barc); 2023 Nov 10; 161(9):382-385. PubMed ID: 37532616
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden.
    Lauppe RE, Liseth Hansen J, Gerdesköld C, Rozenbaum MH, Strand AM, Vakevainen M, Kuusisto J, Gude E, Gustafsson F, Smith JG.
    Open Heart; 2021 Oct 10; 8(2):. PubMed ID: 34645699
    [Abstract] [Full Text] [Related]

  • 18. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F, Scherret E, Knebel F, Messroghli D, Heidecker B, Wetz C, Schatka I, Barzen G, Tschöpe C, Amthauer H, Hahn K.
    Amyloid; 2022 Jun 10; 29(2):92-101. PubMed ID: 34994254
    [Abstract] [Full Text] [Related]

  • 19. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH, Ruberg FL.
    JAMA Cardiol; 2017 Mar 01; 2(3):305-313. PubMed ID: 28196196
    [Abstract] [Full Text] [Related]

  • 20. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
    Zampino S, Sheikh FH, Vaishnav J, Judge D, Pan B, Daniel A, Brown E, Ebenezer G, Polydefkis M.
    Neurology; 2023 May 09; 100(19):e2036-e2044. PubMed ID: 36941075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.